Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis

• Published in: Scientific reports Vol. 9; no. 1; pp. 6410 - 11
• Main Authors: Yokoyama, Keitaro, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.04.2019; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779/109/1942; 692/4022/1585/104/1586; 692/4022/1950/1544; Asian Continental Ancestry Group; Calcium; Calcium (blood); Calcium - metabolism; Dose-Response Relationship, Drug; Female; Hemodialysis; Humanities and Social Sciences; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary - drug therapy; Kidney diseases; Male; Middle Aged; multidisciplinary; Naphthalenes - adverse effects; Naphthalenes - therapeutic use; Parathyroid; Parathyroid hormone; Patients; Phosphorus; Pyrrolidines - adverse effects; Pyrrolidines - therapeutic use; Renal Dialysis; Safety; Science; Science (multidisciplinary); Time Factors; Treatment Outcome; Vitamin D; Vitamin D - metabolism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-42017-z

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD-mineral and bone disorder. Currently, cinacalcet is indicated for the treatment of SHPT; however, cinacalcet is associated with upper gastrointestinal adverse events. Evocalcet has been developed to address these issues, but the long-term safety and efficacy of evocalcet need to be evaluated. To more accurately reflect clinical practice, this phase 3, multicenter, open-label study was specifically designed without a cinacalcet washout period, and focused on those patients who switched from cinacalcet to evocalcet. A total of 137 SHPT patients undergoing hemodialysis were enrolled, of whom 113 switched from cinacalcet to evocalcet. The most frequent type of adverse drug reaction was decreased adjusted calcium. The incidence of gastrointestinal-related adverse events did not increase in a dose-dependent manner as the dose of evocalcet was increased. The percentage of patients achieving the target intact parathyroid hormone concentration increased from 40.9% to 72.3% with 52-week treatment. The corrected serum calcium and phosphorus levels remained largely unchanged throughout the study. The long-term safety and efficacy of evocalcet was confirmed using a clinically relevant intra-subject dose-adjustment strategy in SHPT patients undergoing hemodialysis.